Search the Newsreel

Form 8K ENvue Medical Inc For: 12 August By Investing.com

This article reports that ENvue Medical Inc. filed a Form 8K on August 12. The brief announcement provides no further details regarding the content of the filing. It is published by Investing.com.

Cenovus Energy Inc (CVE) Stock Forecasts

Argus has raised its target price for Cenovus Energy Inc (CVE) to $33.00, citing the company's focus on creating value through its oil sands assets. Cenovus Energy Inc is described as an integrated oil company. The current price for CVE is $29.89.

Here's How Much $1000 Invested In Vulcan Materials 15 Years Ago Would Be Worth Today

Vulcan Materials (NYSE: VMC) has outperformed the market over the last 15 years with an average annual return of 16.08%. An initial investment of $1000 in VMC 15 years ago would now be worth $8,650.68. This demonstrates the significant impact of compounded returns on …

Vulcan Materials Co. stock underperforms Wednesday when compared to competitors

Vulcan Materials Co. (VMC) stock fell by 2.57% on Wednesday, closing at $280.38. This underperformance occurred on a mixed trading day where the S&P 500 Index rose 0.26% and the Dow Jones Industrial Average declined 0.04%. The decline for Vulcan Materials Co. ended a …

FEED Looks 91.4% Undervalued on GF Value™ Despite Distressed Fundamentals

ENvue Medical Inc (NASDAQ: FEED) announced a $50 million equity facility to enhance its ENvue feeding tube navigation system and explore new technologies, despite a nearly 10% pre-market share drop. The company's GF Value™ suggests it is 91.4% undervalued, yet its GF Score™ of …

12 Health Care Stocks Moving In Wednesday's After-Market Session

This article details the performance of 12 healthcare stocks during Wednesday's after-market session, categorized into gainers and losers. Notable gainers include ENvue Medical and Omeros, with Omeros reporting Q2 earnings. Significant losers include Outlook Therapeutics and Valion Bio.

Bravura Solutions FY26 earnings: Revenue, profit, and dividends climb

Kenvue Q2 Deep Dive: Assessing Financial Metrics & Growth Prospects

Kenvue Inc. KVUE, the world's leading pure-play consumer health company, delivered year-over-year improvement in second-quarter 2026, although earnings and sales slightly missed the respective Zacks Consensus Estimate. Net sales rose 3% year over year to $3.96 billion, while organic sales increased 1.6%. Kenvue's second-quarter …

Cenovus Energy Inc. stock rises Wednesday, outperforms market

Cenovus Energy Inc. (CVE) shares rose 1.32% to C$42.11 on Wednesday, outperforming the S&P/TSX Composite Index, which increased by 0.51%. The stock closed 4.6% below its 52-week high of C$44.13. This performance occurred during a generally favorable trading session for the Canadian market.

Vuzix Receives Follow-On Smart Glasses Order from Augmex to Support Its U.S. Market Launch

Vuzix Corporation (NASDAQ: VUZI) has received a follow-on smart glasses order from Augmex, a smart glasses solutions provider. This order, which includes Vuzix M400 and LX1 smart glasses, will support Augmex's launch of its solutions in the United States and continued enterprise deployments across …

ENvue Medical secures $50M equity financing facility By Investing.com

ENvue Medical, Inc. has announced a securities purchase agreement with an institutional investor for an equity financing facility of up to $50 million, subject to stockholder approval. The medical technology company plans to use the capital to advance its technology platform, accelerate the adoption …

ENvue Medical secures up to $50M equity facility to fund growth plans

* ENvue Medical (FEED [https://seekingalpha.com/symbol/FEED]) said on Wednesday that it entered into a securities purchase agreement [https://seekingalpha.com/pr/20616538-envue-medical-secures-equity-financing-facility-of-up-to-50-million-to-support-commercial] with an institutional investor for an equity facility of up to $50M, subject to stockholder approval. * The funding will support the expansion of its ENvue feeding …

ENVUE Medical (FEED) adds $50M equity facility and boosts $59M Series H rights

ENVUE Medical (FEED) has secured a new committed equity facility of up to $50 million with an institutional investor, allowing the company to sell common shares at its discretion, with 40% of net proceeds earmarked for Series X Preferred Stock redemption. Additionally, the company …

ENvue Medical Secures $50 Million Equity Facility; Expands Series H Investment Rights to $59 Million

ENvue Medical has secured a $50 million committed equity facility with an institutional investor and increased its Series H preferred financing Additional Investment Rights to $59 million. The equity facility allows ENvue to sell common shares at 90% of the lowest VWAP over three …

ENvue Medical Eyes AI, Automation, Acquisitions With Up to $50M

ENvue Medical (NASDAQ: FEED) has secured an equity financing facility of up to $50 million, pending stockholder approval, to boost its financial flexibility. The capital is intended to advance its next-generation medical technology platform, including AI and automation technologies, and to fund strategic acquisitions. …

ENvue Medical Secures Equity Financing Facility of Up to $50 Million to Support Commercial Growth, Technology Expansion and Strategic Acquisitions

ENvue Medical, Inc. announced a securities purchase agreement with an institutional investor for an equity facility of up to $50 million, pending stockholder approval. This financing aims to enhance ENvue's financial flexibility, advance its next-generation technology, and support strategic acquisitions and business development. The …

HC Wainwright Issues Negative Estimate for CRVS Earnings

Here's How Much $100 Invested In Cenovus Energy 5 Years Ago Would Be Worth Today

This article analyzes the performance of Cenovus Energy (NYSE: CVE) stock over the past five years. An investment of $100 in CVE five years ago would now be worth $382.95, reflecting an average annual return of 31.17%. The article highlights the significant impact of …

RBC Capital Sticks to Its Hold Rating for Kenvue, Inc. (KVUE)

RBC Capital maintained its Hold rating on Kenvue, Inc. (KVUE) with a $20.00 price target, while Canaccord Genuity also kept a Hold rating with an $18.00 target. Kenvue recently reported increased quarterly revenue and net profit. Insider sentiment for KVUE stock is negative, with …

Is Vulcan Energy Resources (ASX:VUL) Undervalued Following Its Lionheart Construction Start?

Vuzix smart glasses order is expected to support warehouse and field workflows

Vuzix has received a follow-on order from smart glasses solutions provider Augmex for its M400 and LX1 smart glasses. This order continues a series of purchases and is expected to support Augmex's U.S. market launch, alongside ongoing deployments in Europe for enterprise customers in …

IVU TRAFFIC AKTIE: AI-Analysen, Prognose & Kursziel

Bravura Solutions (ASX:BVS) Lifts Profit as Turnaround Broadens

Bravura Solutions (ASX:BVS) Surges as FY26 Results Show Higher Revenue and EBITDA Growth

ENvue Medical Ord Shs (FEED) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for ENvue Medical Ord Shs (FEED), detailing its stock performance, market capitalization, and a comparison with peer companies. The financial forecasting includes expected EPS, revenue, net profit, and EBIT. It highlights that the data was updated on August …

KVUE Maintained by UBS -- Price Target Lowered to $19.00

UBS has lowered its price target for Kenvue Inc (KVUE) from $20.00 to $19.00 while maintaining a Neutral rating. Despite this, GuruFocus calculates KVUE's GF Value™ at $19.70, suggesting the stock is currently undervalued by 3.3%. The company, a consumer health leader with brands …

Vuzix receives smart glasses order from Augmex for U.S. launch By Investing.com

Vuzix Corporation (NASDAQ:VUZI) has received an order for its M400 and LX1 smart glasses from Augmex, a solutions provider for enterprise customers. This order supports Augmex's launch in the United States and expansion across various enterprise verticals. Augmex integrates Vuzix smart glasses with its …

Mizuho Securities Maintains Corvus Pharmaceuticals(CRVS.US) With Buy Rating, Maintains Target Price $30

Mizuho Securities has reiterated its Buy rating for Corvus Pharmaceuticals (CRVS.US) and maintained its price target at $30. This indicates a continued positive outlook from the firm regarding the company's stock performance.

How Investors May Respond To Vulcan Materials (VMC) Completing Its Long-Term US$2 Billion Buyback Program

Vulcan Materials Company (VMC) has completed a US$2 billion share repurchase program, retiring over 14 million shares since 2006. This, combined with increased Q2 2026 sales and net income, reinforces the company's focus on per-share profitability and disciplined capital returns. The article discusses how …

Alivus Life Sciences files FY26 sustainability report with BSI assurance

Alivus Life Sciences FY26 Results: Net profit rises 16% YoY, EBITDA margin hits record

LVMH: Share transactions disclosure

LVMH Paris, August 11th, 2026 The disclosure of share transactions carried out from August 3rd to August 7th, 2026, was sent to the AMF on August 11th 2026. As required by current law, this document is publically available and can be consulted on the …

VUZI Looks 58.2% Overvalued on GF Value™

Vuzix Corp (VUZI) has received a new order for its smart glasses from Augmex, continuing a partnership that began in December 2024. Despite this demand, GuruFocus’ GF Value™ indicates the stock is approximately 58.2% overvalued, trading at a high Price-to-Sales ratio of 33.9 while …

UBS Adjusts Kenvue Price Target to $19 From $20, Maintains Neutral Rating

UBS has adjusted its price target for Kenvue (KVUE) to $19 from $20, while maintaining a Neutral rating on the stock. This adjustment comes shortly after HSBC also revised its price target for Kenvue to $19 from $20, maintaining a Hold rating. The article …

Vulcan Materials Company (NYSE:VMC) to Issue $0.52 Quarterly Dividend

Vulcan Materials Company (NYSE:VMC) announced a quarterly dividend of $0.52 per share, payable on September 2nd to shareholders of record on August 13th. This marks the company's 12th consecutive year of dividend increases, with a healthy payout ratio of 20.7%. Analysts project future earnings …

The Manufacturers Life Insurance Company Buys 84,282 Shares of Corvus Pharmaceuticals, Inc. $CRVS

The Manufacturers Life Insurance Company significantly increased its stake in Corvus Pharmaceuticals (NASDAQ:CRVS) by 481.7% in Q1, purchasing 84,282 shares to bring its total holdings to 101,779 shares valued at $1.49 million. Other institutional investors also expanded their positions, contributing to hedge funds and …